UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

Molecular cancer therapeutics, 2017-06, Vol.16 (6), p.991-1001

2017

Volltextzugriff (PDF)

Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance

Biochemical pharmacology, 2012-04, Vol.83 (8), p.1084-1103

2012

Volltextzugriff (PDF)

Macrophage activation syndrome after granulocyte colony-stimulating factor in a patient with systemic lupus erythematosus

British journal of haematology, 2024-03, Vol.204 (3), p.747-748

2024

Volltextzugriff (PDF)

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Journal of clinical oncology, 2021-09, Vol.39 (26), p.2881-2892

2021

Volltextzugriff (PDF)

Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer

Cancer cell, 2016-10, Vol.30 (4), p.637-650

2016

Volltextzugriff (PDF)

Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

Journal of clinical oncology, 2012-12, Vol.30 (36), p.4515-4523

2012

Volltextzugriff (PDF)

Expression and prognostic impact of lncRNAs in acute myeloid leukemia

Proceedings of the National Academy of Sciences - PNAS, 2014-12, Vol.111 (52), p.18679-18684

2014

Volltextzugriff (PDF)

IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2010-05, Vol.28 (14), p.2348-2355

2010

Volltextzugriff (PDF)

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2134-2139

2012

Volltextzugriff (PDF)

Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

Journal of clinical oncology, 2009-08, Vol.27 (23), p.3842-3848

2009

Volltextzugriff (PDF)

RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

Journal of clinical oncology, 2012-09, Vol.30 (25), p.3109-3118

2012

Volltextzugriff (PDF)

TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1373-1381

2011

Volltextzugriff (PDF)

Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

Journal of clinical oncology, 2012-03, Vol.30 (7), p.742-750

2012

Volltextzugriff (PDF)

Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication

PloS one, 2013-09, Vol.8 (9), p.e74653-e74653

2013

Volltextzugriff (PDF)

Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score

Journal of clinical oncology, 2014-02, Vol.32 (6), p.548-556

2014

Volltextzugriff (PDF)

Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2010-02, Vol.28 (4), p.596-604

2010

Volltextzugriff (PDF)

c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias

Molecular cancer research, 2015-04, Vol.13 (4), p.699-712

2015

Volltextzugriff (PDF)

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

Clinical cancer research, 2009-08, Vol.15 (16), p.5250-5257

2009

Volltextzugriff (PDF)

Fusion Gene-Based Classification of Variant Cytogenetic Rearrangements in Acute Myeloid Leukemia

Genes, 2023-02, Vol.14 (2), p.396

2023

Volltextzugriff (PDF)

Wilms’ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2008-10, Vol.26 (28), p.4595-4602

2008

Volltextzugriff (PDF)

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

Journal of hematology and oncology, 2018-08, Vol.11 (1), p.101-101, Article 101

2018

Volltextzugriff (PDF)

The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2

Molecular cancer therapeutics, 2012-09, Vol.11 (9), p.2033-2044

2012

Volltextzugriff (PDF)

1 – 25 von 664

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(610)
Mit Volltextzugriff
(594)

Publikationsform

Sprache

Englisch
(664)
Japanisch
(41)

Erscheinungsjahr

n.n

Thema

Science & Technology
(323)
Life Sciences & Biomedicine
(305)
Humans
(291)
Oncology
(175)
Female
(171)
Male
(168)
Middle Aged
(144)
Hematology
(139)
Aged
(129)
Adult
(119)
Biological And Medical Sciences
(108)
Medical Sciences
(106)
Acute Myeloid Leukemia
(74)
Hematologic And Hematopoietic Diseases
(72)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(70)
Leukemia, Myeloid, Acute - Drug Therapy
(65)
Aged, 80 And Over
(59)
Leukemia
(59)
Leukemia, Myeloid, Acute - Genetics
(59)
Treatment Outcome
(55)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(214)
Journal Of Clinical Oncology
(49)
Cancer Research
(29)
Leukemia & Lymphoma
(21)
Cancer
(19)
Clinical Lymphoma, Myeloma And Leukemia
(19)
Leukemia Research
(18)
Cancer Genetics And Cytogenetics
(12)
Clinical Cancer Research
(12)
Plos One
(11)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(7)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Macrophage activation syndrome after granulocyte colony-stimulating factor in a patient with systemic lupus erythematosus

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer

Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

Expression and prognostic impact of lncRNAs in acute myeloid leukemia

IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication

Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score

Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

Fusion Gene-Based Classification of Variant Cytogenetic Rearrangements in Acute Myeloid Leukemia

Wilms’ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2

Suchergebnisse filtern